Goldman Sachs initiates a buy on Aster DM Healthcare Ltd with a target price of Rs213. Aster is likely to now enter a phase where it would have to sweat assets, improve cash flows and add leverage.
Solid demand across Gulf Cooperation Council (GCC) and India is likely to drive utilisations, said the Goldman note. It expects utilisations to improve to 65 percent over the next 3 years.
Goldman Sachs expects 17 percent revenue CAGR over the next 3 years. It expects 500 bps margin expansion over FY17-20. The valuations look attractive, and the stock is trading at a discount to Indian/GCC peers.
Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
